360 related articles for article (PubMed ID: 33720508)
1. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
[TBL] [Abstract][Full Text] [Related]
2. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
3. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
[TBL] [Abstract][Full Text] [Related]
4. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
5. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
6. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
7. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
[TBL] [Abstract][Full Text] [Related]
8. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M; Seybold U; Roider J; Härter G; Bogner JR
Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
[TBL] [Abstract][Full Text] [Related]
10. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
12. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
[TBL] [Abstract][Full Text] [Related]
13. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
14. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
[TBL] [Abstract][Full Text] [Related]
16. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Schafer JJ; Zimmerman M; Walshe C; Cerankowski J; Shimada A; Keith SW
Obesity (Silver Spring); 2022 Jun; 30(6):1197-1204. PubMed ID: 35674696
[TBL] [Abstract][Full Text] [Related]
17. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
[TBL] [Abstract][Full Text] [Related]
18. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Schwarze-Zander C; Piduhn H; Boesecke C; Schlabe S; Stoffel-Wagner B; Wasmuth JC; Strassburg CP; Rockstroh JK
HIV Med; 2020 Jul; 21(6):378-385. PubMed ID: 32065713
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
20. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]